Literature DB >> 16563562

2004 Lowbury Lecture: the Western Australian experience with vancomycin-resistant enterococci - from disaster to ongoing control.

J W Pearman1.   

Abstract

The first hospital outbreak of a vancomycin-resistant enterococcus (VRE) in Western Australia (WA) started in the Royal Perth Hospital in July 2001 and initially involved the Intensive Care Unit (ICU) and the Nephrology and Dialysis Units. The outbreak was caused by vancomycin-resistant Enterococcus faecium (VREF) of the vanB genotype. Pulsed-field gel electrophoresis and plasmid analysis of the isolates demonstrated a single-strain outbreak. Despite the isolation of carriers and implementation of all the additional precautions recommended to control VRE, VREF spread rapidly. Two months after the index patient was detected, the epidemic strain had spread to 22 wards and units and one outpatient unit (Satellite Dialysis). Four patients were infected and 64 were colonized. A Hospital VRE Executive Group, which included the Chief Executive and Directors of Clinical Services and Nursing, was formed to eradicate the outbreak and to prevent the epidemic strain from becoming endemic in the hospital. The WA Department of Health agreed to provide substantial extra funding to enable the hospital to use expensive enhanced infection control practices, as follows. Control was handicapped by the slowness of conventional laboratory methods, which took four to five days to identify VRE and allowed environmental contamination and nosocomial transmission to occur before carriers were detected and isolated. A laboratory procedure to make rapid provisional identification of VRE within 30-48h was developed by performing multiplex polymerase chain reaction (PCR) for vanA and vanB genes directly on 24-h selective enrichment broth cultures. On average, four rectal swabs, each collected on separate days, were needed to detect >90% of carriers. In total, 1977 ward contacts were screened after discharge from hospital and 54 (2.73%) were found to be carrying VREF. The electronic labelling and active follow-up of ward contacts resulted in a significant number of carriers being detected who otherwise posed a risk of initiating further outbreaks in hospital if they were re-admitted. The outbreak was terminated after five months and the cost of the enhanced infection control practices was 2,700 000 Australian dollars (1,000,000 pounds sterlings). Ongoing control has been facilitated by targeted active surveillance cultures: on admission to high-risk units (ICU, Burns, Nephrology, Haematology, Bone Marrow Transplant Unit), on transfer out of the ICU to other hospital units, by monthly screening of patients regularly attending Dialysis Units, and by opportunistic laboratory screening of inpatient faecal specimens submitted for Clostridium difficile culture and toxin. Vigilance needs to be maintained as the epidemic strain of VREF remains in the Perth community. Ward contacts of the first outbreak have caused small outbreaks in two hospitals, and seven to 19 sporadic new carriers have been detected annually since the first outbreak. The key elements of the VRE control programme are as follows: To date, this programme has prevented VRE from becoming established in any WA hospital.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563562     DOI: 10.1016/j.jhin.2005.10.017

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  8 in total

1.  Efficient surveillance for healthcare-associated infections spreading between hospitals.

Authors:  Mariano Ciccolini; Tjibbe Donker; Hajo Grundmann; Marc J M Bonten; Mark E J Woolhouse
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

2.  Functional genomics of Enterococcus faecalis: multiple novel genetic determinants for biofilm formation in the core genome.

Authors:  Katie S Ballering; Christopher J Kristich; Suzanne M Grindle; Ana Oromendia; David T Beattie; Gary M Dunny
Journal:  J Bacteriol       Date:  2009-02-13       Impact factor: 3.490

3.  Efficient national surveillance for health-care-associated infections.

Authors:  B A D van Bunnik; M Ciccolini; C L Gibbons; G Edwards; R Fitzgerald; P R McAdam; M J Ward; I F Laurenson; M E J Woolhouse
Journal:  BMC Public Health       Date:  2015-08-28       Impact factor: 3.295

4.  Algorithm for pre-emptive glycopeptide treatment in patients with haematologic malignancies and an Enterococcus faecium bloodstream infection.

Authors:  Xuewei Zhou; Jan P Arends; Lambert Fr Span; Alexander W Friedrich
Journal:  Antimicrob Resist Infect Control       Date:  2013-09-11       Impact factor: 4.887

5.  Silica nanoparticles with encapsulated DNA (SPED) to trace the spread of pathogens in healthcare.

Authors:  Cinzia Ullrich; Anne M Luescher; Robert N Grass; Hugo Sax; Julian Koch
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-10       Impact factor: 4.887

6.  Vancomycin-resistant enterococci outbreak, Germany, and calculation of outbreak start.

Authors:  Ulrich Sagel; Berit Schulte; Peter Heeg; Stefan Borgmann
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

7.  Eradication of an outbreak of vancomycin-resistant Enterococcus (VRE): the cost of a failure in the systematic screening.

Authors:  Lélia Escaut; Samir Bouam; Marie Frank-Soltysiak; Eric Rudant; Faouzi Saliba; Najiby Kassis; Paul Presiozi; Daniel Vittecoq
Journal:  Antimicrob Resist Infect Control       Date:  2013-06-06       Impact factor: 4.887

Review 8.  Enterococcus faecium: from microbiological insights to practical recommendations for infection control and diagnostics.

Authors:  Xuewei Zhou; Rob J L Willems; Alexander W Friedrich; John W A Rossen; Erik Bathoorn
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-10       Impact factor: 4.887

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.